CN111436601A

CN111436601A - Special clinical nutrition formula for pancreatic cancer and preparation thereof

Info

Publication number: CN111436601A
Application number: CN202010393317.1A
Authority: CN
Inventors: 尤俊; 季敬东
Original assignee: Shanghai Own Medic High Tech Medical Industrial Co ltd
Current assignee: Shanghai Own Medic High Tech Medical Industrial Co ltd
Priority date: 2020-05-11
Filing date: 2020-05-11
Publication date: 2020-07-24

Abstract

The invention discloses a special clinical nutrition formula for pancreatic cancer, which comprises the following components in parts by weight: 15-45 parts of carbohydrate, 30-60 parts of protein, 0.2-1 part of folic acid, 0.0005-0.004 part of vitamin A and vitamin B₆0.0005-0.004 portion of vitamin B₁₂0.0005 to 0.004 portion, 0.6 to 2 portions of vitamin C, 0.002 to 0.04 portion of vitamin E, 0.000001 to 0.00002 portion of vitamin D, 0.01 to 0.02 portion of zinc, 0.2 to 2 portions of calcium, 0.00005 to 0.00025 portion of selenium, 5 to 20 portions of fat, 2 to 10 portions of new resource food, 4 to 30 portions of medicinal and edible components and 10 to 25 portions of dietary fiber, wherein the new resource food comprises one or more of arginine, glutamine, probiotics, L-carnitine, β -hydroxy- β -calcium methylbutyrate and curcumin.

Description

Special clinical nutrition formula for pancreatic cancer and preparation thereof

Technical Field

The invention relates to the field of formula foods with special medical application, in particular to a special clinical nutritional formula for pancreatic cancer and a preparation method thereof.

Background

Pancreatic cancer is a common malignant tumor of the digestive tract, and the incidence rate of pancreatic cancer is on the increasing trend year by year in recent years. One statistic of the american cancer society shows that each year new pancreatic cancer in the united states, mainly ductal adenocarcinoma, totaled 46400 deaths of 39600. Common symptoms include weight loss, abdominal pain, and jaundice. Diagnosis requires a CT examination. The main treatment method is surgical treatment assisted by chemotherapy and radiotherapy. Since many patients are in advanced stage at the time of visit, pancreatic cancer has a poor prognosis with a 5-year survival rate of less than 5%.

To date, the pathogenesis of pancreatic cancer is unclear and, absent specific clinical symptoms and early diagnostic tests, 25% of patients are already in locally advanced stages at the time of treatment, 60% are often accompanied by loss of surgical opportunity for metastasis of local or distant organs, and the five-year survival rate for unresectable patients is less than 5%. Its mortality rate is in the 5 th to 6 th positions of all malignant tumors.

Most pancreatic cancers are exocrine tumors, derived from ductal and acinar cells. Pancreatic endocrine tumors originate in the islets of langerhans and in gastrin-producing cells, and secrete a variety of hormones. Although these tumors occur most frequently in the pancreas, they may also occur in other organs, particularly in the duodenum, jejunum and lung. There are two main manifestations: functional tumors and non-functional tumors. Functional tumors secrete large amounts of specific hormones, resulting in a variety of symptoms, including the appearance of multiple endocrine tumors, tumors or newly added organisms affecting 2 or more endocrine glands, usually parathyroid, pituitary, thyroid or adrenal glands. Non-functional tumors can cause biliary or duodenal obstruction symptoms, gastrointestinal bleeding, or abdominal mass.

Pancreatic cancer onset is associated with a number of risk factors, including both environmental and genetic factors. Changes in human lifestyle can lead to changes in the incidence of pancreatic cancer, smoking being the most important factor in pancreatic cancer, and a case-control study showed that smokers had a 2.2-fold increased risk of pancreatic cancer compared to non-smokers, whereas smoking cessation reduced this risk to 1.64-fold. Long-term development of diabetes type II is another important high-risk factor, and the risk of pancreatic cancer is increased by 1.51 times for patients with type II diabetes for more than 10 years. Body Mass Index (BMI) is another independent risk factor, and people with BMI >35 are at a 1.55-fold higher risk of pancreatic pain than people with BMI. Other environmental risk factors such as chronic alcohol abuse and chronic pancreatitis increase the risk of pancreatic cancer by 1.46-fold and 1.73-fold, respectively. Studies have shown that malnutrition is one of the major causes of increased incidence of complications and mortality in pancreatic cancer patients.

From the above, it is clear that the nutritional status of a patient is crucial in the prognosis of a disease. Pancreatic cancer has a poorer prognosis, a 5-year survival rate of less than 5%, and the nutritional status of the patient is more important than other malignant tumors. Pancreatic cancer patients receiving chemotherapy experience nausea, vomiting, etc. reactions that result in decreased intake and absorption of nutrients. With the prolongation of the chemotherapy time, the chemotherapy drugs are accumulated in the body, and secondary infection, bone marrow depression and other symptoms can follow, thereby affecting the metabolic condition of the whole body.

Therefore, it is an important research direction to give patients with pancreatic cancer full nutritional support to improve the quality of life of the patients.

Disclosure of Invention

The special clinical nutritional formula for pancreatic cancer, which is provided by the invention for solving the problems in the prior art, provides high-quality protein, n-3 and n-6 unsaturated fatty acids through reasonable dietary blending, selects various vitamins, minerals, medicinal and edible foods and new resource foods, relieves the clinical symptoms of patients and improves the nutritional status of the patients.

In order to achieve the purpose, the invention adopts the following technical scheme:

the invention provides a special clinical nutritional formula for pancreatic cancer, which comprises the following components in parts by weight: 15-45 parts of carbohydrate, 30-60 parts of protein, 0.2-1 part of folic acid, 0.0005-0.004 part of vitamin A and vitamin B₆0.0005-0.004 portion of vitamin B₁₂0.0005 to 0.004 portion, 0.6 to 2 portions of vitamin C, 0.002 to 0.04 portion of vitamin E, 0.000001 to 0.00002 portion of vitamin D, 0.01 to 0.02 portion of zinc, 0.2 to 2 portions of calcium, 0.00005 to 0.00025 portion of selenium, 5 to 20 portions of fat, 2 to 10 portions of new resource food, 4 to 30 portions of medicinal and edible components and 10 to 25 portions of dietary fiber;

the new resource food comprises one or more of arginine, glutamine, probiotics, L-carnitine, β -hydroxy- β -calcium methylbutyrate and curcumin.

Preferably, the arginine comprises one or more of L-arginine, L-arginine hydrochloride and L-arginine-aspartic acid.

Preferably, the probiotic bacteria comprise one or more of bifidobacterium, lactobacillus, streptococcus, lactobacillus acidophilus NCFM, animal bifidobacterium Bb-12, bifidobacterium lactis HN019, bifidobacterium lactis Bi-07, lactobacillus rhamnosus L GG, lactobacillus rhamnosus HN001, lactobacillus fermentum CECT5716 and bifidobacterium breve M-16V.

Preferably, the protein source is one or more of hydrolyzed whey protein powder, concentrated whey protein powder, soy protein isolate, whole egg powder, bovine colostrum powder, whole milk powder, albumin peptide, soybean peptide, marine fish oligopeptide, wheat oligopeptide, corn oligopeptide powder, α -whey protein powder and lactoferrin.

Preferably, the vitamin B6 is derived from one or both of pyridoxine hydrochloride and pyridoxal 5' -phosphate.

Preferably, the vitamin B12 is one or more of cyanocobalamin, cyanocobalamin hydrochloride and hydroxocobalamin.

Preferably, the vitamin E is derived from one or more of d- α -tocopherol, dl- α -tocopherol, d- α -tocopheryl acetate and dl- α -tocopheryl acetate.

Preferably, the vitamin A is derived from one or two of retinyl acetate, retinyl palmitate, all-trans retinol, β -carotene.

Preferably, the medicinal and edible components comprise one or more of Poria, Glycyrrhrizae radix, herba Houttuyniae, fructus Gardeniae, pericarpium Citri Tangerinae, herba Taraxaci, endothelium corneum Gigeriae Galli and Concha Ostreae.

In a second aspect, the invention provides a preparation method of the special clinical nutritional formula for pancreatic cancer, which comprises the following steps:

s1: weighing the raw materials according to the parts by weight in the claim 1, and mixing the vitamins, minerals, medicinal and edible food raw materials and new resource food raw materials to obtain a first mixture;

s2: mixing the first mixture obtained in the step S1 with carbohydrate, and stirring for 8-15min to obtain a second mixture;

s3: putting the second mixture obtained in the step S2 and other materials into a mixing stirrer according to a gradually increasing principle, and stirring for 18-22min to obtain a special clinical nutritional formula for pancreatic cancer;

s4: testing the pancreatic cancer-specific clinical nutritional formula of step S3; and weighing, recording and repacking after the test is qualified.

By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:

through reasonable diet blending, high-quality protein, n-3 and n-6 unsaturated fatty acid are provided, and various vitamins, mineral substances, medicinal and edible foods and new resource foods are selected, so that the clinical symptoms of patients are relieved, the nutritional status of the patients is improved, the adverse reactions during operations, chemoradiotherapy are relieved, and the prognosis of the patients is improved. Wherein arginine and vitamin B₆Vitamin B₁₂The combination of vitamin E, vitamin A and folic acid can inhibit the growth of tumor and prolong the survival time of patients.

Detailed Description

Pancreatic cancer patients are one of the high risk factors affecting postoperative recovery, due to operative trauma, early postoperative fasting, and postoperative stress response, which can lead to decreased energy intake, accelerated tissue breakdown and protein loss, resulting in organ dysfunction, weight loss, and thus increased incidence of complications and increased mortality. Therefore, it is necessary to strengthen the nutritional support during the perioperative period and improve the nutritional status of the patients, thereby reducing the occurrence of operative complications, prolonging the life span of the patients and improving the life quality of the patients.

The body mass index and other various tissue cell observation indexes of the pancreatic cancer patient after the operation are reduced compared with those before the operation, which shows that the protein catabolism of the patient after the operation, especially the skeletal muscle protein is enhanced. The massive decomposition of the protein causes a series of symptoms of delayed recovery after the operation of the patient, such as anorexia, weak constitution, fatigue and weakness, relatively prolonged recovery time and the like. In addition, the relative value of the body fat of the pancreatic cancer patient is lost remarkably after operation. Therefore, appropriate amounts of amino acids and fat milk should be supplemented after surgery.

In one embodiment of the present invention, the fat comprises one or more of fish oil microcapsule powder, linseed oil microcapsule powder, evening primrose oil microcapsule powder, olive oil microcapsule powder, medium chain triglyceride powder, docosahexaenoic acid oil, arachidonic acid oil, and tea oil microcapsule powder.

Glutamine is the most abundant amino acid in blood, and accounts for 50% of free amino acid in the body. 75% of the glutamine pool is present in skeletal muscle, the remainder being mainly present in the liver. In the case of a stress such as a decrease in glutamine in blood and tissues of a patient suffering from a wound or a tumor in a catabolic state or a trauma, the stored glutamine may be consumed by 50% or more, the plasma concentration may be decreased by 20% to 30%, and the release from skeletal muscle may be increased as a result of the decrease in intracellular glutamine, and the glutamine in the host tissue may be decreased.

Glutamine is a respiratory fuel for rapidly proliferating cells in the human body and is also a precursor for nucleic acid and protein synthesis. Glutamine has the effects of promoting protein synthesis and inhibiting protein decomposition.

In a preferred embodiment of the invention, the glutamine is L-glutamine.

Arginine, an essential amino acid, promotes the formation of intestinal mucosal trophic factors such as citrulline and ornithine, improves the functions of T cells and macrophages, and produces NO having an immune defense effect. Arginine not only stimulates the release of thymus to T lymphocytes through the conduction of the nervous system, but also increases the secretory activity of mononuclear lymphocytes in spleen to interleukin 2, thereby improving the immune defense and immunoregulation action of the T lymphocytes.

In one embodiment of the invention, arginine includes one or more of L-arginine, L-arginine hydrochloride, and L-arginine-aspartic acid.

The probiotics is called as a microecological preparation or a viable bacteria preparation, and refers to normal flora capable of surviving in an intestinal ecosystem or exotic bacteria with regulation and beneficial effects, the probiotics has the action mechanism of ① colonization antagonism, maintaining intestinal flora balance, inhibiting pathogenic bacteria reproduction, ② promoting expression of intestinal closely-connected related protein, ③ improving intestinal immune function and improving organism immune function, ④ timely eliminating intestinal carcinogens, promoting release of anticancer substances and inducing apoptosis of tumor cells, so that timely supplementing the probiotics has important significance for preventing and treating systemic infection, systemic inflammatory response syndrome and multiple organ dysfunction syndrome caused by intestinal flora imbalance during chemotherapy.

In a preferred embodiment of the invention, the probiotic bacteria comprise one or more of Bifidobacterium, Lactobacillus, Streptococcus, Lactobacillus acidophilus NCFM, Bifidobacterium animalis Bb-12, Bifidobacterium lactis HN019, Bifidobacterium lactis Bi-07, Lactobacillus rhamnosus L GG, Lactobacillus rhamnosus HN001, Lactobacillus fermentum CECT5716, Bifidobacterium breve M-16V.

L-carnitine is mainly positioned in the inner membrane of mitochondria in biological cells, and has the functions of transporting long-chain fatty acid from the outside of the mitochondrial membrane to the inside of the membrane in a carrier form, namely in the form of fatty acid carnitine, promoting β -oxidation of fatty acid and regulating the ratio of acyl CoA/CoA.

β -hydroxy- β -methylbutanoic acid calcium is a natural compound produced in leucine metabolism, and has effects of promoting muscle protein synthesis, inhibiting muscle protein decomposition, maintaining cell integrity, improving immune function and reducing inflammatory reaction.

Curcumin is a phenolic pigment extracted from turmeric and is also the main active ingredient of turmeric. A large number of researches show that curcumin has biological effects of resisting infection, inflammation, immune regulation, oxidation and mutation and the like.

The high-quality protein is beneficial to the absorption and utilization of a human body digestive absorption system, and can comprehensively and uniformly supplement 8 essential amino acids required by the human body, otherwise negative nitrogen balance is easy to occur, and the immunity is influenced.

In an embodiment of the present invention, the protein source is one or more of hydrolyzed whey protein powder, concentrated whey protein powder, soy protein isolate, whole egg powder, bovine colostrum powder, whole milk powder, albumin peptide, soybean peptide, marine fish oligopeptide, wheat oligopeptide, corn oligopeptide powder, α -whey protein powder and lactoferrin.

In one embodiment of the invention, the dietary fiber is derived from one or more of cereal dietary fibers such as inulin, polydextrose, galacto-oligosaccharide, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, resistant dextrin, soybean fiber and the like.

In recent years, researchers have considered that plasma hyperhomocysteine has a positive correlation with the risk of developing pancreatic cancer. Homocysteine exists in two forms in the body, mostly in association with albumin and a small amount free homocysteine. Generally, we refer to homocysteine as total homocysteine, whereas homocysteine in plasma reflects the intracellular concentration of homocysteine. The homocysteine metabolic pathway includes two: one is in the presence of 5-methyltetrahydrofolic acid and vitamin B₁₂To produce methionine; second, in vitamin B₆Cystathionine is produced by the action of (1). It can be seen that homocysteine is metabolized with folic acid and vitamin B₁₂And vitamin B₆Have close relationship between them.

Thus folic acid, vitamin B₆Is a protective factor for pancreatic cancer, plasma folate level, vitamin B₆The decreased level can increase the risk of pancreatic cancer, indirectly affect the synthesis and repair functions of DNA, and affect cell metabolism.

In a preferred embodiment of the invention, vitamin B₆Derived from one or two of pyridoxine hydrochloride and pyridoxal 5' -phosphate; vitamin B₁₂One or more of cyanocobalamin, cyanocobalamin hydrochloride and hydroxycobalamin.

The study suggests that dietary folate reduction can reduce S-adenosylmethionine, which is used as a direct donor of a one-carbon unit and affects methylation of cytosine, resulting in DNA synthesis errors; meanwhile, the folic acid is reduced, so that the generation of 5, 10-methyltetrahydrofolic acid is reduced, further, the synthesis of thymine is reduced, and the DNA repair is influenced. If folic acid is continuously deficient, deoxynucleotides are unbalanced in precursor aggregation, and obstacles occur in DNA repair, resulting in DNA double strand breaks, chromosome breaks, changes in oncogenes or tumor suppressor genes, and tumor occurrence. The folate content of the pancreas is second only to the liver, and animal experiments show that a decrease in folate in food will decrease the exocrine function of the pancreas. Therefore, folate may have a more important role for the pancreas than other organs.

In a preferred embodiment of the invention, the folic acid is derived from pteroylglutamic acid.

Vitamin E is a fat-soluble vitamin with antioxidant effect, which can enhance the synthesis of enzyme protein and the function of oxidase on microsomes, and can effectively protect cell membranes from being damaged by peroxide, and the insufficient content of vitamin E can cause metabolic disturbance and aggravation of free radical chain reaction, so that oxidative peroxidation damage of DNA, protein, enzyme and biological membranes is caused, and various diseases are induced. Animal deficient vitamin E can cause various pathological changes such as cell injury, necrosis, etc., and various metabolic changes in tissues, and in animal tissues deficient in vitamin E, mitochondrial oxygen consumption is increased to cause oxidative phosphorylation disorder, resulting in ATP production reduction. A large amount of superoxide anion free radicals are generated in the process of pancreatic canceration, so that substances with anti-oxidation effect in a body are reduced, when the concentration of vitamin E is remarkably reduced, an oxidation-anti-oxidation system is unbalanced, the damage of the free radicals to pancreatic cells is caused, the normal metabolism in the cells is influenced by the existence of continuous oxygen free radical damage, and the DNA damage face of the pancreatic cells is mutated to cause the pancreatic cell canceration.

In patients with pancreatic cancer, the vitamin E concentration in the body of the patient is obviously reduced along with the gradual development of the disease from acute pancreatitis, chronic pancreatitis and pancreatic cancer, which indicates that the oxidation-oxidation imbalance in the body of the patient is gradually aggravated. In the process of canceration of pancreatic cells, free radicals are the main cause of cell DNA mutation, and vitamin E has the function of resisting oxygen free radicals, so that the remarkable reduction of the concentration of the vitamin E in pancreatic cancer patients is closely related to the canceration of the pancreatic cells.

In a preferred embodiment of the invention, vitamin E is derived from one or more of d- α -tocopherol, dl- α -tocopherol, d- α -tocopheryl acetate and dl- α -tocopheryl acetate.

Vitamin D₃Can effectively inhibit the proliferation of pancreatic cancer PANC-1 cells and promote the apoptosis of the cells, and the effect is probably related to the blockage of a Hedgehog signaling pathway. Vitamin D₃Can be used as a novel Hedgehog signal path blocker to play a role in resisting pancreatic cancer. Low vitamin D in serum₃Will increase the risk of colon cancer, breast cancer, prostate cancer, while supplementing vitamin D₃The risk thereof can be significantly reduced.

In a preferred embodiment of the invention, the vitamin D is derived from one or both of cholecalciferol, ergocalciferol.

Vitamin a is normally converted to all-trans retinoic acid during metabolism, which plays an important role in growth, development and cell differentiation. As pancreatic tumors develop, they signal the stellate cells to activate them, releasing their vitamin a, which is not metabolized in the stellate cells. The activated stellate cells form dense connective tissue around the tumor, and cancer cells can spread to other parts by means of the tissue, and the connective tissue can limit the direct effect of the anticancer drugs on the tumor. Researchers artificially initiate the metabolic transformation process of vitamin A in stellate cells in a laboratory, and the generated all-trans retinoic acid effectively prevents the stellate cells from 'transforming' the surrounding environment of tumors, reduces the formation of connective tissues and ensures that cancer cells are not easy to grow and spread.

In a preferred embodiment of the present invention, vitamin a is one or more selected from retinyl acetate, retinyl palmitate, all-trans retinol, and β -carotene.

The treatment of traditional Chinese medicine mainly adopts syndrome differentiation, the symptoms are treated in case of emergency, the root cause is treated in case of slow, and both internal and external treatments are used. (1) Improving vital qi of organism, and enhancing disease resistance, disease prevention and self-repairing ability of organism; (2) improving symptoms of patients such as debilitation, spontaneous perspiration, night sweat, pain, etc.; (3) can regulate the immune function of an organism, inhibit the proliferation of tumor cells, induce the apoptosis of the tumor cells and prevent or delay the metastasis of tumors; (4) alleviate the toxic and side effects of traditional Chinese medicines with excessive power of radiotherapy and chemotherapy or attack of pathogenic factors or consume too much healthy qi, and prolong the life cycle.

The main chemical components of tuckahoe include pachymaran, β -pachymaran, glucose, sucrose and fructose, as well as ergosterol, stedane, cellulose, triterpenes, caprylic acid, lauric acid, histidine, choline, protein, fat, enzyme, adenine, gum, etc. the Chinese medicinal materials include dry sclerotium of tuckahoe, which is a kind of polyporaceae fungus.

The main chemical components of licorice are triterpene saponin, one of which is glycyrrhizin, potassium salt and calcium salt of glycyrrhizic acid generated by combining β -glycyrrhetinic acid and glucuronic acid, and further contains flavone compounds and coumarin compounds.

The herba Houttuyniae contains saccharide, protein, fat, calcium, phosphorus and volatile oil, and the volatile oil contains methyl n-nonyl ketone, myrcene, decanoic acid, decanol, and lauraldehyde. The medicine has pungent taste and cold nature. The pharmacological action is as follows: antibacterial; resisting viruses; enhancing immunity, and promoting phagocytic function of leukocyte and macrophage; anti-inflammatory and analgesic effects; and (3) resisting tumors.

Gardenia contains geniposide, chlorogenic acid and other ingredients. The medicinal material is bitter in taste and cold in nature. The pharmacological action is as follows: tranquilizing and relieving pain; cooling and relieving heat; anti-inflammatory.

The volatile oil in pericarpium Citri Tangerinae is mainly limonene, and the medicinal material has sweet taste and cold property. The pharmacological action is as follows: the effect on digestive systems; anti-inflammatory and anti-allergic. Coix seed, sweet and light in flavor, cool in nature. The pharmacological action is as follows: resisting cancer; and (4) resisting bacteria. The dandelion is bitter and sweet in taste and cold in nature. The pharmacological action is as follows: performing spectrum bacteriostasis; resisting stomach injury; anti-tumor; clear heat and remove toxicity, relax bowels.

Ji Nei jin is sweet in flavor and cold in nature. The pharmacological action is as follows: promoting digestion; strengthening body constitution, and delaying aging. The oyster contains calcium carbonate, calcium phosphate and calcium sulfate, and contains glycogen, taurine, 10 essential amino acids, glutathione, vitamins and the like. The medicinal material is salty in taste and slightly cold in nature. The pharmacological action is as follows: enhancing immunity; tranquilizing and relieving pain; and adjusting the electrolyte balance.

The present invention will be described in detail and specifically with reference to the following examples to facilitate better understanding of the present invention, but the following examples do not limit the scope of the present invention.

Example 1

This example provides a clinical nutritional formula specific for pancreatic cancer, comprising the following components (as described in table 1):

TABLE 1 clinical nutritional formula specific for pancreatic cancer in example 1

The preparation method of the special clinical nutritional formula for pancreatic cancer comprises the following steps:

s1: weighing raw materials according to table 1, and mixing the vitamins, minerals, medicinal and edible source and new resource food raw materials to obtain a first mixture;

s2: mixing the first mixture obtained in the step S1 with carbohydrate, and stirring for 10min to obtain a second mixture;

s3: and (5) putting the second mixture obtained in the step (S2) and other materials into a mixing stirrer according to a gradually increasing principle, and stirring for 20min to obtain the special clinical nutritional formula for pancreatic cancer.

Example 2

This example provides a clinical nutritional formula specific for pancreatic cancer, comprising the following components (as described in table 2):

TABLE 2 clinical nutritional formula specific for pancreatic cancer in example 2

s1: weighing the raw materials according to table 2, and mixing the vitamins, minerals, medicinal and edible source and new source food raw materials to obtain a first mixture;

Example 3

This example provides a clinical nutritional formula specific for pancreatic cancer, comprising the following components (as described in table 3):

TABLE 3 Special clinical nutritional formula for esophageal cancer

s1: weighing the raw materials according to table 3, mixing the vitamins, minerals, medicinal and edible source and new source food raw materials to obtain a first mixture;

Application example 1

The test subjects were 45 patients with pancreatic cancer of similar physical condition, and the patients were randomly divided into three groups of 15 persons, the control group was administered with placebo, and the experimental group was administered with the clinical nutritional formula for pancreatic cancer provided in examples 1 to 3, each at a time of 100mg, continuously administered for 2 months, and weighed, and the results are shown in table 4 below.

TABLE 4 examples 1-3 effects of specialized clinical nutritional formulas for pancreatic cancer

Application example 2

1. Establishment of human pancreatic cancer mouse tumor implantation model

1.1 taking out the necrotic tissue from the fresh tumor tissue, cutting into about 3 cubic millimeters in diameter, and inserting into the subcutaneous dorsal part of a female mouse which is 6 weeks old and about 18 g.

1.2 mice were placed into a mouse IVC system for feeding.

1.3 waiting for the tumor to form about 15mm, excising subcutaneous tumor aseptically, selecting solid mass, cutting the material into 3 cubic mm small blocks, and transplanting to another mouse.

1.4 tumor passage is carried out by the method, and mice of the third generation all appear subcutaneous transplantation tumors and have small difference of tumor sizes.

2. Treatment study of laboratory animals

Mice were evenly distributed to each group according to tumor volume, with more than 10 per group. The 2 groups of mice had free access to water at the following doses. After one month, the experiment was terminated, and the subcutaneous tumor on the back was removed and weighed, and the average value was taken.

Control group: drinking sterile distilled water;

experimental groups: the formula prepared in example 1 was infused with warm water and infused into the stomach every day.

TABLE 5 treatment study results of the Experimental animals

	Tumor weight (g)
		Control group	1.10
Experimental group	0.85

The embodiments of the present invention have been described in detail, but the embodiments are merely examples, and the present invention is not limited to the embodiments described above. Any equivalent modifications and substitutions to those skilled in the art are also within the scope of the present invention. Accordingly, equivalent changes and modifications made without departing from the spirit and scope of the present invention should be covered by the present invention.

Claims

1. The special clinical nutritional formula for pancreatic cancer is characterized by comprising the following components in parts by weight: 15-45 parts of carbohydrate, 30-60 parts of protein, 0.2-1 part of folic acid, 0.0005-0.004 part of vitamin A and vitamin B₆0.0005-0.004 portion of vitamin B₁₂0.0005 to 0.004 portion, 0.6 to 2 portions of vitamin C, 0.002 to 0.04 portion of vitamin E, 0.000001 to 0.00002 portion of vitamin D, 0.01 to 0.02 portion of zinc, 0.2 to 2 portions of calcium, 0.00005 to 0.00025 portion of selenium, 5 to 20 portions of fat, 2 to 10 portions of new resource food, 4 to 30 portions of medicinal and edible components and 10 to 25 portions of dietary fiber;

2. The pancreatic cancer-specific clinical nutritional formula of claim 1, wherein said arginine comprises one or more of L-arginine, L-arginine hydrochloride, and L-arginine-aspartic acid.

3. The pancreatic cancer specific clinical nutritional formula of claim 1, wherein said probiotic comprises one or more of bifidobacterium, lactobacillus, streptococcus, lactobacillus acidophilus NCFM, bifidobacterium animalis Bb-12, bifidobacterium lactis HN019, bifidobacterium lactis Bi-07, lactobacillus rhamnosus L GG, lactobacillus rhamnosus HN001, lactobacillus fermentum CECT5716, bifidobacterium breve M-16V.

4. The clinical nutritional formula for pancreatic cancer patients of claim 1, wherein the protein source is one or more of hydrolyzed whey protein powder, concentrated whey protein powder, soy protein isolate, whole egg powder, bovine colostrum powder, whole milk powder, albumin peptide, soy peptide, marine fish oligopeptide, wheat oligopeptide, corn oligopeptide powder, α -whey protein powder, and lactoferrin.

5. The pancreatic cancer-specific clinical nutritional formula according to claim 1, wherein said vitamin B is vitamin B₆Derived from one or two of pyridoxine hydrochloride and pyridoxal 5' -phosphate.

6. The pancreatic cancer-specific clinical nutritional formula according to claim 1, wherein said vitamin B is vitamin B₁₂One or more of cyanocobalamin, cyanocobalamin hydrochloride and hydroxycobalamin.

7. The pancreatic cancer-specific clinical nutritional formula of claim 1, wherein said vitamin E is derived from one or more of d- α -tocopherol, dl- α -tocopherol, d- α -tocopheryl acetate, and dl- α -tocopheryl acetate.

8. The pancreatic cancer-specific clinical nutritional formula according to claim 1, wherein said vitamin a is derived from one or both of retinyl acetate, retinyl palmitate, all-trans retinol, β -carotene.

9. The special clinical nutritional formula for pancreatic cancer according to claim 1, wherein the medicinal and edible components comprise one or more of Poria cocos, licorice, houttuynia cordata, cape jasmine fruit, dried orange peel, dandelion, endothelium corneum gigeriae galli and oyster.

10. A method of preparing a clinical nutritional formula specific for pancreatic cancer according to any one of claims 1 to 9, comprising the steps of:

s3: and (5) putting the second mixture obtained in the step (S2) and other materials into a mixing stirrer according to a gradually increasing principle, and stirring for 18-22min to obtain the special clinical nutritional formula for pancreatic cancer.